Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data presented at the European Academy of Dermatology and Venereology (EADV) ...

4 Approximately half of patients with EGPA have adult-onset severe eosinophilic asthma (SEA) and often have sinus and nasal symptoms. 3,8,9 Fasenra is only the second biologic approved to treat this ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the full agenda for the 15th annual Clarivate Pharmavision India conference. The 15th edition of ...

A biologic is a therapeutic substance that is produced through a biological process (often involving biotechnology methods), rather than chemical synthesis (as for traditional pharmaceuticals).

Bevacizumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% ...

India's Serum to double investment in Biocon's unit to $300 mln April 25, 2023 Worldcategory India's Biocon raises $129 mln from Kotak to fund biosimilars deal February 22, 2023 Reuters ...

SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Tanvex BioPharma ("Tanvex" or the "Company"), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products ...

If passed, the law would modify the Biologics Price Competition and Innovation Act of 2009 (BPCIA) under which a sponsor may seek approval of a “biosimilar” product under the Public Health ...

An AstraZeneca Plc unit settled a federal patent-infringement lawsuit with a Samsung Biologics Co. subsidiary after failing to block its biosimilar version of the $500,000-per-patient drug Soliris.

current data standards for interchangeable biosimilars and oppose treating all biosimilars as interchangeable with the originator biologic medicines they copy, according to a recent survey of 270 U.S.

biosimilars are only similar to their reference biologics. They are also much newer in the industry – the first approved biosimilar in Europe launched in 2006 and the US in 2015. And biosimilars ...

The Hyderabad-based firm is adopting a two-pronged approach to biosimilars by developing innovative products as well as contract manufacturing. Through its CuraTeQ Biologics, a wholly-owned ...